Phase I clinical study of a WT1-W10 peptide immunotherapy combined with standard treatment against diffuse midline glioma (WT1-TR-DMG).
Phase 1
- Conditions
- glioblastoma multiforme
- Registration Number
- JPRN-UMIN000025452
- Lead Sponsor
- Cancer Vaccination Therapy Research Network Central Office, Department of Immunology, Kochi Medical School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
One or more of the following criteria leads to exclusion of the subject. 1)Uncontrollable infections, including active tuberculosis 2)Severe comorbidities (e.g. malignant hypertension, severe congestive heart disease, severe ischemic heart disease, myocardial infarction within 3 months, end-stage liver insufficiency, uncontrollable diabetes mellitus, severe pneumonitis etc.) 3)After the bone marrow implantation 4)Severe psychological disorders 5)Being enrolled in other clinical trials 6)Once enrolled in this study, but was disqualified for some reasons (Double enrollment is prohibited.) 7)Disqualified by the doctors due to some medical, psychological and/or social problems
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Degree and frequency of adverse events (> grade 3)
- Secondary Outcome Measures
Name Time Method